ArticleAnimal microbiome2025
Linarin alleviates enterotoxigenic Escherichia coli-induced small intestinal mucosal barrier damage in a piglet model by modulating the gut microbiota.
Article in Animal microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artemisia argyi-enriched fermented soybean meal alleviates ETEC K88-induced intestinal injury in mice in association with gut microbiota remodeling and purine metabolic alterations.BMC veterinary research · 2026Article
- Oligomeric ultranano hydrogen water improves flock uniformity, antioxidant capacity and intestinal health in growth phase layer-type chickens.Poultry science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the preventive effects of dietary linarin supplementation on Enterotoxigenic coli (ETEC) induced small intestinal barrier dysfunction in weaned piglets via gut microbiota modulation.
resultsTwenty-four weaned piglets were randomly assigned to four experimental groups. The four treatments were as follows: BD + NB (basal diet and orally administered nutrient broth), LN + NB (basal diet supplemented with 150 mg/kg linarin, and orally administered nutrient broth), BD + ETEC (basal diet and orally administered ETEC), LN + ETEC (basal diet supplemented with 150 mg/kg linarin, and orally administered ETEC). The results showed that linarin lowers the serum levels of diamine oxidase (DAO), endotoxin, and D-lactate (P < 0.05). Linarin significantly increased villus height and villus/crypt ratio (P < 0.01), while decreasing crypt depth in the duodenum. jejunum, and ileum (P < 0.05). Additionally, Linarin increased the number of goblet cells within villus-crypt units in the duodenum. jejunum, and ileum (P < 0.05). Linarin significantly enhanced intestinal barrier function, upregulated detoxification pathways, reduced epithelial apoptosis, and improved nutrient transporter expression in the small intestine." Linarin decreased the relative abundances of Actinobacillus, Romboutsia, Enterococcus, and Terrisporobacter, consequently modulating key metabolic pathways, including arginine and proline metabolism, steroid biosynthesis, and cysteine and methionine metabolism.
conclusionsDietary linarin supplementation mitigates ETEC-induced intestinal mucosal barrier dysfunction and enhances nutrient assimilation via targeted modulation of microbial communities and associated metabolic networks, thereby providing a new strategy for the prevention and treatment of ETEC diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.